GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-08-11| Trials & Approvals

FDA Finds Carcinogen In Merck’s Diabetes Drug, Allows Continued Sales To Avoid Shortage

by Joy Lin
Share To

The US FDA has found traces of contaminants in certain samples of Merck’s popular diabetes drug Januvia (sitagliptin). The drugmaker has confirmed that some batches of the drug were found to contain Nitroso-STG-19 (NTTP), a possible carcinogen.

Januvia is essential for some Type 2 diabetes patients to manage their high blood sugar. To prevent a potential shortage of the drug, the FDA is temporarily allowing Merck to continue to sell Januvia with NTTP above the agency’s acceptable daily intake of 37 ng. According to calculations, the difference in cancer risk would be minimal, the agency said. However, the FDA would not accept sales of drugs containing daily intake levels of 246.7 ng and above. 

Related article: Merck Dangles $1.1 Billion For Cerevance To Discover New Targets For Alzheimer’s

Contaminations In Drug Products

NTTP belongs to a class of compounds called nitrosamines, some of which are thought to be carcinogenic, or cancer-causing. The compounds are common in daily life, and are found in water and food. However, only prolonged exposure to higher-than-acceptable levels of nitrosamines could increase the risk of cancer. 

Nitrosamine contamination has plagued many drug companies in recent years, and has forced some to recall batches of drugs. N-nitrosodimethylamine (NDMA), another nitrosamine, has been repeatedly found in metformin, a diabetes drug. Metformin recalls began in early 2020, with New Jersey-based Viona Pharmaceuticals recently recalling 23 lots of metformin this January. 

Pfizer had to recall batches of Chantix, its anti-smoking treatment due to the presence of nitrosamines. The contamination issue has since extended to blood pressure medications Accuretic and Accupril, forcing Pfizer to stop selling the drugs. 

Merck has asserted that there would be no significant impact to the supply of Januvia. The company has also implemented more quality controls to make sure its drugs will satisfy the FDA’s interim limits. 

News of the contamination caused the company’s shares to dip sharply before recovering up 1.2% at closing. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
Easing the Mental Health Burden: How MDMA, Psilocybin, and Other Psychedelics May Open Doors for Treating PTSD, Addiction, and Autism
2025-01-28
Drug Promotion, Nonprescription Pathways, and Advanced Manufacturing: FDA’s Key Focus Areas in 2024 and What’s Next for 2025
2025-01-23
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top